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resenilin-1 null mutation (PS1 
 
 
 
/
 
 
 
) in mice is asso-
ciated with morphological alterations and defects
in cleavage of transmembrane proteins. Here, we
demonstrate that PS1 deﬁciency also leads to the formation
of degradative vacuoles and to the aberrant translocation of
presynaptic 
 
 
 
- and 
 
 
 
-synuclein proteins to these organelles
in the perikarya of primary neurons, concomitant with
signiﬁcant increases in the levels of both synucleins.
Stimulation of autophagy in control neurons produced a
similar mislocalization of synucleins as genetic ablation of
P
 
PS1. These effects were not the result of the loss of PS1
 
 
 
-secretase activity; however, dysregulation of calcium
channels in PS1 
 
 
 
/
 
 
 
 cells may be involved. Finally,
colocalization of 
 
 
 
-synuclein and degradative organelles was
observed in brains from patients with the Lewy body variant
of AD. Thus, aberrant accumulation of 
 
 
 
- and 
 
 
 
-synuclein
in degradative organelles are novel features of PS1 
 
 
 
/
 
 
 
neurons, and similar events may promote the formation of
 
 
 
-synuclein inclusions associated with neurodegenerative
diseases.
 
Introduction
 
Presenilin-1 (PS1) is one of several proteins linked to early
onset, familial Alzheimer’s disease (AD). PS1 null (
 
 
 
/
 
 
 
)
mice die in utero, and PS1 
 
 
 
/
 
 
 
 embryos have multiple
abnormalities including smaller size, skeletal malformations,
nervous system hemorrhages, and fewer neurons (Wong et
al., 1997). PS1 was initially shown to play a role in the
intramembrane cleavage of the amyloid precursor protein
(APP; De Strooper et al., 1998) and Notch (De Strooper et al.,
1999) and was subsequently documented to cleave additionally
a growing list of type I transmembrane proteins including
Erb-b4, E-cadherin, the low density lipoprotein-related
protein, nectin-1
 
 
 
, and CD44, among others (Selkoe and
Kopan, 2003). PS1 has additional functions unrelated to
proteolytic cleavage, including effects on the 
 
wnt
 
 signaling
pathway (Kang et al., 1999), cell adhesion junction assembly
(Georgakopoulos et al., 1999), calcium channel regulation
(Leissring et al., 2000; Yoo et al., 2000), trafficking of
secretory proteins to the cell surface (Naruse et al., 1998;
Kaether et al., 2002) and kinesin-dependent vesicle transport
(Kamal et al., 2001; Pigino et al., 2003). Thus, the diverse
pathologies seen in PS1 
 
 
 
/
 
 
 
 mice likely reflect the pleiotropic
activities of PS1.
Here, we have identifed a novel phenotype characterized by
clusters of autophagic lysosomal organelles and the aberrant
localization of synuclein proteins to perikarya in neurons
from PS1 
 
 
 
/
 
 
 
 mice. Synucleins are a family of small acidic
proteins comprised of 
 
 
 
-, 
 
 
 
-, and 
 
 
 
-synuclein (George,
2002). Abnormal cytoplasmic aggregation of 
 
 
 
-synuclein
has been implicated as the primary pathology in a variety
of neurodegenerative diseases including Parkinson’s disease
(PD), dementia with Lewy bodies, the Lewy body variant of
AD (LBVAD), multiple system atrophy, and neurodegener-
ation with brain iron accumulation, which are collectively
termed 
 
 
 
-synucleinopathies (Duda et al., 2000). 
 
 
 
- and
 
 
 
-Synuclein accumulations also are seen in some 
 
 
 
-synucle-
inopathies (Galvin et al., 1999). In normal brains, 
 
 
 
- and
 
 
 
-synuclein are localized predominantly to central nervous
system presynaptic terminals (Maroteaux et al., 1988; Jakes
et al., 1994), especially near synaptic vesicles (George et al.,
1995; Iwai et al., 1995).
The presynaptic location of 
 
 
 
- and 
 
 
 
-synuclein suggests
they play a role in synaptic function (Withers et al., 1997),
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perhaps via interaction with synaptic vesicles (Maroteaux
and Scheller, 1991). Depletion of 
 
 
 
-synuclein in cultured
hippocampal neurons or mice selectively diminishes the dis-
tal pool of synaptic vesicles in presynaptic terminals impli-
cating 
 
 
 
-synuclein in vesicle positioning or recycling (Mur-
phy et al., 2000; Cabin et al., 2002). Synucleins may be
additionally involved in signal transduction (Nakajo et al.,
1993; Shibayama-Imazu et al., 1993; Ostrerova et al., 1999;
Iwata et al., 2001) or have chaperone-like functions (Ostre-
rova et al., 1999; Souza et al., 2000).
Furthermore, because a hydrophobic fragment of 
 
 
 
-synu-
clein was isolated from amyloid plaques in AD (Ueda et al.,
1993) and 
 
 
 
-synuclein–positive Lewy bodies frequently oc-
cur in familial AD (FAD) brains associated with PS1 muta-
tions (Lippa et al., 1998), the formation of 
 
 
 
-synuclein in-
clusions may be linked to mechanisms underlying AD. We
examined this possibility and show here that degradative or-
ganelles increase and selectively accumulate 
 
 
 
- and 
 
 
 
-synu-
clein in PS1 
 
 
 
/
 
 
 
 neurons, thereby implicating PS1 defi-
ciencies in mechanisms of 
 
 
 
- and 
 
 
 
-synuclein trafficking and
degradation which could play a role in 
 
 
 
-synuclein lesions in
neurodegenerative diseases such as FAD and LBVAD.
 
Results
 
PS1 deficiency resulted in the formation of enlarged 
lysosomes in fibroblasts and primary neurons
 
Examination by differential interference contrast micros-
copy revealed the presence of enlarged organelles in immor-
talized fibroblasts derived from PS1 
 
 
 
/
 
 
 
 mice. These
enlarged structures occupied a significant volume of the
cytoplasm (Fig. 1 A), distending the flat surface of the fibro-
blasts. To determine the identity of these structures, we
probed the cells with a panel of organelle-specific antibod-
ies. Antibodies to lysosomal membrane-associated protein 2
(Lamp-2) selectively labeled these organelles, suggesting a ly-
sosomal origin (Fig. 1, B and C). Similarly, an accumulation
of Lamp-2 immunolabeled organelles also was detected in
primary neurons derived from PS1 
 
 
 
/
 
 
 
 mice (Fig. 1, D
and E) but not from those derived from PS1 
 
 
 
/? mice (Fig.
1 F), suggesting that the accumulation of these organelles is
a general property of PS1 deficiency. Significantly, these or-
ganelles were not present in PS2 
 
 
 
/
 
 
 
 cells, suggesting that
this phenotype is independent of PS2 (unpublished data).
To further confirm that the enlarged structures represent
lysosomal vacuoles, we used transmission EM to visualize
large clusters of lysosomal organelles that occupied a signifi-
cant portion of PS1 
 
 
 
/
 
 
 
 neuronal perikarya (Fig. 1, G and
H), but not control PS1 
 
 
 
/? neurons (Fig. 1 I). These or-
ganelles consisted of both electron-dense and multilamellar
material. Thus, ultrastructural analyses suggest that these or-
ganelles are likely to represent enlarged lysosomal or auto-
phagic vacuoles.
 
 
 
- and 
 
 
 
-synuclein are selectively mislocalized to 
enlarged lysosomes in PS1 
 
 
 
/
 
 
 
 neurons
 
To determine the biological consequences of these enlarged
organelles, we examined the distribution of a number of syn-
Figure 1. Enlarged lysosomal organelles are 
visible in PS1  /  cells. (A) Differential contrast 
interference imaging of the cell surface of PS1  /  
fibroblasts demonstrated that a significant volume of 
the cells was occupied by large, spherical structures 
(arrows point to examples of enlarged vesicular 
structures). Lamp-2 immunolabeling of PS1  /  (B) 
or PS1  /? (C) fibroblasts demonstrated that these 
enlarged structures expressed lysosomal marker 
proteins and were present only within PS1  /  
cells. Similar accumulations of Lamp-2–positive 
organelles were detected in (D and E) PS1  /  
but not (F) PS1  /? mouse primary neurons. 
Transmission EM analysis of PS1  /  (G and H) or 
PS1  /?. (I) Neurons demonstrated that PS1  /  
neurons contain large clusters of organelles. H is a 
higher magnification of the boxed area in G. *, 
denotes nucleus. Bars: (B–D and F) 10  m; (E) 5  m; 
(G and I) 1  m; (H) 200 nm. 
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aptic and cytoskeletal proteins in PS1 
 
 
 
/
 
 
 
 neurons. 
 
 
 
- and
 
 
 
-synuclein, two presynaptic proteins, were selectively redis-
tributed to neuronal perikarya. In mouse PS1 
 
 
 
/
 
 
 
 (not de-
picted) or PS1 
 
 
 
/? neurons cultured for 10 d, both 
 
 
 
-synu-
clein (Fig. 2 A) and 
 
 
 
-synuclein (not depicted) were almost
completely localized to punctate structures immunoreactive
for the presynaptic marker proteins. However, when PS1 
 
 
 
/
 
 
 
neurons were immunolabeled with antibodies to either
 
 
 
-synuclein (Fig. 2 B) or 
 
 
 
-synuclein (Fig. 2 C), most synu-
clein immunoreactivity did not colocalize with the synaptic
marker proteins, but instead was localized to vesicles clus-
tered around nuclei and extending into the proximal pro-
cesses of 30–40% of PS1  /  neurons (Fig. 2, B and C, ar-
rows). Double labeling of PS1  /  neurons with antibodies
to  -synuclein and Lamp-2 demonstrated a clear colocaliza-
tion of the perikaryal synuclein immunoreactivity with the
enlarged, Lamp-positive organelles (Fig. 2, E and F), not
seen in PS1  /? neurons (Fig. 2 D). Higher magnification
images revealed both Lamp-2 and synuclein immunoreactiv-
ity colocalized to the outer edges of these lysosomal struc-
tures, producing a ringlike appearance (Fig. 2 F). Similar
colocalization was demonstrated with antibodies to addi-
tional lysosomal proteins (Lamp-1, cathepsin D; unpub-
lished data).
Immuno-EM was conducted to determine the spatial rela-
tionship of the perikaryal  - and  -synuclein proteins to
these structures. Although no synuclein immunoreactivity
was found near the nuclei of PS1  /? neurons (Fig. 2 G), sy-
nuclein immunoreactivity was associated with the aberrant
lysosomal organelle clusters of PS1  /  neurons, most of
which was localized along the limiting membrane of these
organelles (Fig. 2, H and I), similar to the pattern seen by
immunofluorescence. Although some synuclein immunore-
activity appeared to be intralysosomal, it also is plausible
that  - and  -synuclein are bound to the cytoplasmic sur-
face of these lysosomes.
Expression levels of  - and  -synuclein are increased 
in PS1  /  neurons
Expression of both  - and  -synuclein was increased in 10-
d-old PS1  /  neurons relative to control neurons (Fig. 3).
In contrast, levels of other synaptic or axonal proteins, in-
cluding synaptophysin, synapsin I, neurofilament-L (NFL),
and tau, were nearly unchanged or increased less than two-
fold in PS1  /  neurons (Fig. 3).
Human PS1 rescues synuclein aberrations 
in PS1  /  neurons
As shown in Fig. 4, the alterations in  - and  -synuclein
were specifically due to the absence of PS1, based on analysis
of primary cortical cultures from PS1  /  mice rescued
with a transgenic human WT presenilin construct (Qian et
al., 1998). No somatic synuclein deposits were found in
PS1-WT rescued cultures (Fig. 4 C), and synuclein protein
levels were not increased in these cells (Fig. 4 E). Similarly,
in neuronal cultures from PS1  /  mice rescued with
Figure 2. Perinuclear synuclein accumulations 
can be visualized in association with lysosomes 
in PS1  /  neurons. (A) PS1  /? or (B and C) 
PS1  /  primary neuronal cultures were immuno-
labeled with antibodies to synaptophysin (green) 
and  -synuclein (A and B, red; Ab SNL-1) or 
synapsin I (green) and  -synuclein (C, red; Ab Syn 
207). In PS1  /  neurons,  - and  -synuclein are 
found in perinuclear locations that do not contain 
other presynaptic proteins (B and C, arrows). (D–F) 
Colocalization of lysosomal-associated membrane 
protein 2 (LAMP-2) with perinuclear synuclein 
accumulations in PS1  /  neurons. (D) PS1  /? 
or (E and F) PS1  /  neurons cultured for 10 d 
were immunolabeled with antibodies to synuclein 
(Syn 202, red) and LAMP-2 (ABL93, green). (G–I) 
Immuno-EM of synuclein association with perinu-
clear multivesicular and autophagic organelles 
in PS1  /  neurons. Synuclein is not found in 
association with lysosomes in PS1  /? neurons 
(G, arrowhead) but is localized to enlarged 
lysosomal organelles in PS1  /  neurons (H and I). 
*, denotes nucleus. Bars: (A–E) 10  m; (F) 5  m; 
(H) 500 nm; (G and I) 100 nm.338 The Journal of Cell Biology | Volume 165, Number 3, 2004
transgenic human FAD PS1-A246E,  - and  -synuclein
were not found in somatic accumulations (Fig. 4 D), and
levels of both  - and  -synuclein were similar to those seen
in control cultures (Fig. 4 E). Thus, PS1 reexpression in PS1
null neurons is sufficient to rescue the abnormal  - and
 -synuclein phenotype, and mutant PS1 appears to rescue
equally well as WT PS1.
Cause of increased synuclein expression
Because increased steady-state levels of  - and  -synuclein
may be due to either increases in the synthesis of these pro-
teins or decreases in degradation, we examined the levels of
synuclein mRNA, translation of protein, and protein turn-
over at timed intervals in PS1  /  and PS1  /? neurons.
Synuclein mRNA increased steadily with time in both cell
types (Fig. 5 A), however, there were no differences in the
levels of synuclein mRNA between PS1  /  and PS1  /?
neurons at any time point examined. Nevertheless, despite
the identical mRNA levels between the two cell types, the
amount of newly synthesized  -synuclein after 1.5 h of met-
abolic labeling was demonstrably higher in PS1  /  neu-
rons at all times in culture tested, although  -synuclein pro-
tein synthesis did not differ (Fig. 5 B). Previous studies have
likewise suggested that regulation of  -synuclein protein ex-
pression likely occurs at the posttranscriptional level (Pe-
tersen et al., 1999).
Turnover of radiolabeled proteins was measured over a
4-d period to assay synuclein degradation.  -Synuclein has
been shown to be very stable in transfected HEK293 and
PC12 cells (Okochi et al., 2000). Although the half-life of
endogenous  - and  -synuclein in PS1  /? neurons was
 45 and 50 h, respectively, in PS1  /  neurons the half-
life of both  - and  -synuclein nearly doubled (Fig. 5 C).
Thus, the increased levels of  -synuclein in PS1  /  neu-
rons appears to be the result of both increased production
and decreased degradation, whereas the increase in  -synu-
clein is due primarily to decreased degradation. The half-life
of synaptophysin was unchanged in PS1  /  neurons rela-
tive to control cells.
Figure 3.  - and  -synuclein are overexpressed in PS1  /  
neurons. (A) Increased levels of both  - and  -synuclein in PS1  /  
lysates were demonstrated with the synuclein antibodies Syn 202 
and Syn 214. Other synaptic proteins including synapsin I and 
synaptophysin were increased only slightly in PS1  /  neurons. NSE 
was used as a loading control. (B) 
125I-quantification of synuclein, 
synaptophysin, synapsin I, NFL, and tau levels relative to NSE. Error 
bars represent SD.
Figure 4. Expression of human wild-
type or FAD mutant PS1 eliminated 
synuclein perinuclear accumulations 
and overexpression. (A–D) Immunola-
beling of neuronal cultures with antibodies 
to synapsin I (green) and  - and  -synu-
clein (red, Syn 202). Neuronal cultures 
were generated from mice (A) PS1  / , 
(B) PS1  /?, (C) PS1  /  rescued with 
wild-type human PS, or (D) PS1  /  
rescued with PS1 containing FAD mutant 
A246E. Perinuclear synuclein accumula-
tions appeared only in PS1  /  neurons 
(A, arrow). *, denotes nucleus. Bar, 10  m. 
(E) Western blots of lysates from 10-d-old 
cultures. The mouse PS1 carboxy-terminal 
fragment was present only in PS1  /? 
cultures, and the larger human fragment 
was present only in the two rescue lines. 
 - and  -synuclein levels were increased 
solely in the PS1  /  cultures. NSE was 
used as a loading control.Synuclein in presenilin  /  neurons | Wilson et al. 339
Trafficking of other proteins is not impaired 
in PS1  /  neurons
The accumulation of synucleins within the perinuclear re-
gion of PS1  /  neurons suggests that the normal transport
of these proteins to the synapse may be impaired. Altered
transport of several transmembrane proteins has been dem-
onstrated in PS1  /  neurons (Naruse et al., 1998; Kaether
et al., 2002). Furthermore, kinesin-directed vesicle transport
is reduced in PS1  /  neurons due to increased phosphory-
lation of kinesin (Pigino et al., 2003).  - and  -synuclein
have been shown to be transported to the synapse via the fast
rate component as well as by slow components a and b
(Jensen et al., 1999; Li et al., 2004). The distribution of ve-
sicular proteins transported by the kinesin-dependent fast
rate component, such as synaptophysin and synapsin I, or the
slow rate component protein NFL and  -tubulin was unal-
tered between PS1  /  and PS1  /? neurons (Figs. 1 and
6), and none of these proteins was found to colocalize with
 - and  -synuclein within neuronal perikarya. Similar results
were seen using antibodies to a large number of axonal and
synaptic proteins (unpublished data). Thus, gross differences
in axonal transport do not appear to account for the accumu-
lation of synuclein in PS1  /  neurons. Furthermore, over-
expression of the PS1 substrates APP or Notch in PS1  / 
cells failed to demonstrate a colocalization of these proteins
with the Lamp-positive organelles (unpublished data), dem-
onstrating that these organelles are not simply a cellular re-
pository for these uncleaved PS1 substrates.
Furthermore, although  - and  -synuclein accumulate in
PS1  /  neuronal perikarya, there does not appear to be a
Figure 5. Examination of synuclein synthesis and 
degradation in PS1  /  neurons. (A) Northern blot 
and PhosphorImager quantification of synuclein 
mRNA levels in PS1  /  and PS1  /? neurons 
after multiple DIV.  - and  -synuclein appeared as 
one band on the Northern blot. There were no 
differences in the levels of synuclein mRNA. (B) 
Immunoblot and quantification of synuclein 
translation. Translation of  -synuclein, but not 
 -synuclein, was significantly increased in PS1  /  
neurons. (C) Pulse chase and quantification of 
synuclein and synaptophysin turnover. The average 
half-life of both  - and  -synuclein was increased 
in PS1  /  neurons, whereas that of synaptophysin 
was unchanged between the two cell types. Error 
bars represent SD.340 The Journal of Cell Biology | Volume 165, Number 3, 2004
complete block in their transport, as some colocalization
of  - and  -synuclein with other synaptic marker pro-
teins could be visualized in punctate patterns characteristic
of synapses even within PS1  /  neurons (Figs. 1 and
6). Quantification of the colocalization of synucleins and
synaptophysin in putative synaptic puncta demonstrated
 50% colocalization in both PS1  /  and control cells
(Fig. 6 G). Furthermore, we found by EM that the distal
pool of synaptic vesicles appeared to be similar between the
two cell types (unpublished data), lending support to the
view that synuclein transport to the synapses was unaltered
in PS1  /  neurons (unpublished data) because depletion
of synuclein at the synapses results in a diminution of this
particular pool of vesicles (Murphy et al., 2000; Cabin et
al., 2002).
Pharmacological manipulation of autophagy impacts 
perikaryal  - and  -synuclein localization
To determine whether the aberrant translocation of  - and
 -synuclein is due to the formation of autophagic vacuoles,
we stimulated the formation of enlarged organelles by treat-
ing PS1  /? neurons with staurosporine, which causes hy-
peraccumulation of large membrane-bound structures im-
munoreactive for lysosomal proteins (Adamec et al., 2000).
After treatment with 100 nM staurosporine for 48 h, a sig-
nificant number of cells displayed Lamp-2–positive intracel-
lular organelles (Fig. 7, D–F) morphologically similar to
those seen in PS1  /  neurons. Control untreated PS1  /?
neurons did not develop such Lamp-2–positive organelles
(Fig. 7, A–C). Immunolabeling with the antibody Syn 202
demonstrated that  - and  -synuclein colocalized with
Lamp proteins along the outer membrane of these or-
ganelles. Thus, the formation of Lamp-positive organelles is
sufficient to induce perikaryal colocalization of synucleins to
these organelles.
The formation of these organelles in PS1  /  cells may
be due to the loss of  -secretase activity. To address this,
PS1  /? neurons were treated for 7 d with  -secretase inhib-
itors, including transition-state analogs L-685,458 (Shear-
man et al., 2000) and III-21C (Esler et al., 2002), difluo-
roketone DFK-167 (Wolfe et al., 1998), dipeptide aldehyde
2-Napthyl-VF-CHO (Sinha and Lieberburg, 1999), and
LiCl (Phiel et al., 2003). Cells were treated with doses
shown previously to reduce the  -secretase cleavage of APP
overexpressed in PS1  /? neurons (Wilson et al., 2002; and
unpublished data). None of the compounds increased the
percentage of neurons demonstrating Lamp-2–positive au-
tophagic organelles, nor was there evidence of perikaryal
localization of synuclein proteins (Fig. 8). Thus, the ap-
pearance of enlarged Lamp-2–positive organelles and the
mislocalization of synuclein in PS1  /  cells were not cor-
related with the absence of  -secretase activity in these cells.
To gain further insight into the possible mechanism lead-
ing to the formation of enlarged autophagosomes, we ma-
nipulated intracellular calcium levels in PS1  /  neurons.
Multiple intracellular signaling events have been demon-
strated to influence degradative pathways, including dys-
regulation of intracellular calcium levels (for review see
Codogno et al., 1997). Absence of PS1 has been linked to
excessive activation of capacitative calcium channels in the
plasma membrane responsible for refilling the ER calcium
stores, which can be reversed by SKF 96365, a specific in-
hibitor of the channel (Leissring et al., 2000; Yoo et al.,
2000). Thus, we sought to determine if SKF96365 affected
the localization of synuclein proteins in enlarged lysosomal
organelles. Treatment of 10-d-old PS1  /  neuronal cul-
tures with SKF 96365 for 48 h resulted in a dose-dependent
decrease in both somatic synuclein accumulations (Fig. 9)
and proliferation of Lamp-positive organelles (not depicted).
In contrast, treatment with thapsigargin, an inhibitor of the
ER calcium/ATPase responsible for maintaining the high
concentrations of calcium within the ER, had no significant
effect on the number of cells displaying either phenotype,
Figure 6. Axonal transport is not impaired in PS1  /  neurons. 
The localization of proteins redistributed by the fast rate component 
of axonal transport (A and B, synaptophysin, green) as well as the 
slow rate component (C and D, NFL, green; E and F,  -tubulin, green) 
was compared with that of  - and  -synuclein (red, Syn 202) in 
(A, C, and E) PS1  /  neurons and (B, D, and F) PS1  /? neurons. 
None of the proteins examined appeared localized to the perinuclear 
synuclein accumulations. *, denotes nucleus. Bar, 5  m. Arrows 
illustrate perinuclear synuclein accumulation. (G) The percentage of 
synaptophysin-positive putative synapses colabeled with synuclein 
immunoreactivity. Error bars represent SD.Synuclein in presenilin  /  neurons | Wilson et al. 341
nor did culturing the cells in medium containing a 10-fold
reduction in calcium concentrations. Thus, the formation of
enlarged autophagic vacuoles and the mislocalization of the
synucleins are likely due to the deregulation of capacitative
calcium in the absence of PS1.
Finally, we examined if somatic colocalization of synuclein
and lysosomes is associated with disease pathology. Accumu-
lations of enlarged lysosomes have been visualized early in the
pathogenesis of AD (Cataldo et al., 1995), autophagy in the
substantia nigra has been documented in PD (Anglade et al.,
1997), and cell body  -synuclein accumulation in Lewy bod-
ies is a classical feature of many  -synucleinopathies. In pa-
tients with LBVAD, irregular accumulations of  -synuclein
that resemble those seen in PS1  /  neurons were observed
in neuronal cell bodies (Fig. 10 A, arrows) as well as close to
the nuclei of nonneuronal cells (Fig. 10 A, arrowheads). Tis-
sue from nondiseased controls (Fig. 10 B) and PD patients
(not depicted) demonstrated only diffuse neuropil synuclein
immunoreactivity. Likewise, Lamp-2 immunoreactivity was
more pronounced in LBVAD dentate gyrus (Fig. 10 C) than
controls (Fig. 10 D). Examination of serial sections showed
similar cellular localization of  -synuclein and Lamp-2 in
LBVAD hippocampi (compare Fig. 10 E with Fig. 10 F; and
compare Fig. 10 G with 10 H). Thus, the perikaryal localiza-
tion of  -synuclein to lysosomal structures in neuronal cell
cultures may have counterparts in disease pathology.
Discussion
We have demonstrated the formation of large vacuolar au-
tophagic and/or lysosomal organelles in PS1  /  cells and
showed that  - and  -synuclein, normally presynaptic pro-
teins, are found in association with these abnormal struc-
tures in PS1  /  neuronal perikarya. Concomitantly, there
was a large increase in the expression levels of both proteins.
Similar perinuclear association with degradative organelles
was demonstrated in cells treated with staurosporine to in-
duce autophagy. Furthermore, the phenotype could be re-
versed by pharmacological blockade of capacitative calcium
channels, suggesting that the role of PS1 in the maintenance
of intracellular calcium stores may be involved.
The lysosomal Lamp-positive enlarged organelles de-
scribed here in PS1  /  neurons are morphologically simi-
lar to those seen in hereditary lysosomal storage diseases
(Walkley, 1998) or aging (Cuervo and Dice, 2000), in neu-
rons after injury (Hornung et al., 1989), or after treatment
with lysosomal inhibitors (Bi et al., 1999) or cell stressor
agents (Adamec et al., 2000). Organelles with morphologi-
cal features similar to those described here and containing
the novel protein telencephalin were reported previously in
PS1  /  neurons (Annaert et al., 2001). Interestingly, lyso-
somal and/or autophagic organelles are also increased in
PC12 cells overexpressing  -synuclein containing the famil-
ial PD A53T mutation (Stefanis et al., 2001), as well as in
Figure 7. Induction of autophagy with stauro-
sporine stimulates the association of synucleins 
with perinuclear lysosomal organelles. PS1  /? 
neurons were treated with 100 nM staurosporine 
for 48 h to induce autophagy. Immunolabeling of 
(A–C) untreated and (D–F) treated neurons with 
antibodies to Lamp-2 (A and D, green) and synuclein 
(B and E, Syn 202, red). The overlap is shown in C 
and F. Nuclei were counterstained with DAPI (blue). 
Bar, 5  m.
Figure 8. Loss of PS1  -secretase activity does not result in the 
formation of enlarged perinuclear organelles. PS1  /? neurons were 
treated for 7 d with the  -secretase inhibitors L-685,458 (1  M), 
DFK-167 (50  M), III-31C (5  M), 2-Napthyl-VF-CHO (20  M), or 
LiCl (5 mM), and analyzed by light microscopy for Lamp-2 and 
synuclein immunoreactivity. None of these compounds increased 
the percentage of neurons containing Lamp-2–positive enlarged 
perinuclear organelles, nor did they induce the localization of 
synuclein proteins to this site. 100 nM staurosporine treatment for 
48 h was included as a positive control. Asterisks indicate that the 
results are statistically significant, P   0.005. Error bars represent SD.342 The Journal of Cell Biology | Volume 165, Number 3, 2004
hypothalamic cell lines transfected with WT  -synuclein
(Hsu et al., 2000). An up-regulation of synuclein protein ex-
pression has also been documented in a variety of injury
models, including ischemia (Ishimaru et al., 1998), adminis-
tration of MPTP (Vila et al., 2000) or dopamine (Gomez-
Santos et al., 2003), and targeted developmental injury to
the striatum of rats (Kholodilov et al., 1999). Additionally,
increased expression of both  - and  -synuclein was found
in a mouse model of the lysosomal storage disorder GM2
gangliosidosis (Suzuki et al., 2003) and PD frequently oc-
curs in patients with Gaucher’s disease (Bembi et al., 2003).
Somatic synuclein immunoreactivity can be induced by mi-
tochondrial inhibitor pesticides such as rotenone (Betarbet
et al., 2000), as well as physical injury such as nerve trans-
section (Moran et al., 2001) and has been documented in
the vicinity of lipofuscin granules, age-related tertiary lyso-
some derivatives, in MPTP-induced Parkinsonism in mice
(Meredith et al., 2002).
The exact mechanism driving the accumulation of en-
larged Lamp-positive organelles in PS1  /  neurons re-
mains unknown. Presenilins themselves were demonstrated
recently within the lysosomal system (Pasternak et al., 2003)
suggesting that they may play a critical role in the functions
of these organelles. We have demonstrated that the forma-
tion of autophagic vacuoles in PS1  /  cells is likely unre-
lated to PS1  -secretase activity, as treatment of control neu-
Figure 9. Inhibition of capacitative calcium 
channels eliminates the perinuclear distribution 
of synucleins in PS1  /  neurons. PS1  /  and 
PS1  /? neurons cultured for 10 d in vitro were 
treated with SKF 96365 or thapsigargin, or incubated 
in low Ca
2  medium for 48 h. Representative 
images of (A) untreated PS1  /? neurons, (B) 
untreated PS1  / neurons, or (C) PS1  /  neurons 
treated with 500 nM SKF 96365 are shown. Nuclei 
are counterstained with DAPI (blue). Bar, 10  m. 
(D) Quantification of the percentage of neurons 
displaying perinuclear synuclein immunoreactivity. 
Error bars represent SD.
Figure 10. Perinuclear  -synuclein deposits colocalize 
with Lamp-immunoreactivity in dentate hilar neurons 
from patients with LBVAD. Hippocampal tissue from (A) 
LBVAD patients immunolabeled with Syn 303 revealed 
perinuclear synuclein immunoreactivity in neuronal cell 
bodies (arrows) and neurites (*) as well as near the nuclei 
of nonneuronal cells (arrowheads), which are not seen in 
tissue from (B) nondiseased controls. Similarly, Lamp-2 
immunoreactivity is increased in (C) LBVAD dentate 
gyrus relative to (D) controls. A comparison of synuclein 
immunoreactivity (E and G, Syn 303) with Lamp-2 immu-
noreactivity in adjacent sections (F and H, Lamp-2 C20) 
demonstrated similar localization of the two proteins in 
cell bodies. Bars: (A–D) 30  m; (E–H) 10  m.Synuclein in presenilin  /  neurons | Wilson et al. 343
rons with  -secretase inhibitors failed to reproduce these
effects. However, the decrease in enlarged lysosomal or-
ganelles in PS1  /  neurons treated with a capacitative cal-
cium channel inhibitor implicates an involvement of the ER
calcium stores in the formation of these structures. ER Ca
2 
stores are refilled via activation of capacitative calcium chan-
nels on the plasma surface. The activity of these cell surface
refilling channels is significantly increased in PS1  /  cells
(Yoo et al., 2000). A role for ER calcium stores in the regula-
tion of autophagic degradation has been described, although
the exact mechanism remains elusive (Codogno et al.,
1997). We have demonstrated that inhibition of calcium re-
filling with SKF 96365 was sufficient to block formation of
autophagic/lysosomal organelles and concomitant localiza-
tion of  - and  -synuclein in PS1  /  cells. Surprisingly,
we noted that thapsigargin, which inhibits the ER calcium/
ATPase and thereby lowers ER calcium levels by passive dif-
fusion, did not have the same effect as SKF 96365. This may
suggest that the requirements for the formation of degrada-
tive organelles are more complex than simply the size of the
ER pool, or alternatively may reflect the fact that capac-
itative calcium entry can be stimulated by thapsigargin-
induced ER calcium release (Putney and McKay, 1999).
Synucleins may accumulate within Lamp-positive degrada-
tive organelles because they normally are degraded at this site.
Inhibition of lysosomes with ammonium chloride reduces
 -synuclein turnover (Paxinou et al., 2001), and  -synuclein
can be degraded by autophagy when overexpressed in PC12
cells (Webb et al., 2003). The observation that the rate of  -
and  -synuclein turnover is diminished in PS1  /  neurons
is consistent with this hypothesis. However, synucleins may
be degraded normally by proteases such as calpain localized at
the presynapse (Mishizen-Eberz et al., 2003), and thus the
decrease in protein turnover in PS1  /  neurons may sim-
ply reflect the spatial discrepancy between the somatic pool
of synucleins and the presynaptic proteases.
Alternatively,  - and  -synuclein may be associated with
the cytoplasmic surface of the enlarged organelles. High
magnification confocal and immuno-EM demonstrated that
synucleins are concentrated as ringlike immunoreactivity
near the outer membrane of enlarged degradative organelles.
Synucleins can bind to small synthetic vesicles in vitro
(Davidson et al., 1998) and the perinuclear organelles may
simply act as a nonspecific sink for synuclein binding. Alter-
natively, it is possible that synucleins play a more active role
in the formation or maintenance of autophagic organelles in
PS1  /  neurons. Multiple presynaptic vesicle proteins ei-
ther have homology with proteins regulating organelles in
the degradative pathway or are themselves active at both
sites, including isoforms of synaptotagmin (Martinez et al.,
2000), synaptobrevin (Advani et al., 1999), and syntaxin
(Darsow et al., 1997; Nakamura et al., 2000).
The aberrant  -,  -synuclein localization and expression
in PS1  /  neurons is not a direct model for the patho-
biology in Lewy body diseases or other synucleinopathies.
Several key characteristics distinguish the two phenomena,
including the presence of  -synuclein and absence of neu-
rofilaments, ubiquitinated proteins, and filamentous forms
of   -synuclein in the PS1  /  somatic accumulations.
Nevertheless, the structures described herein may partially
recapitulate early events in the development of  -synuclein
pathology, as the accumulation of  -synuclein in the perinu-
clear region may lead to the formation of a nidus for fibrilli-
zation. Evidence for up-regulation of autophagy has been
visualized in PD brain tissue (Anglade et al., 1997). We have
demonstrated that  -,  -synuclein associate with degrada-
tive organelles structurally similar to these, both in cell cul-
ture and in human disease tissue, and that this association is
accompanied by a significant increase in the intracellular ex-
pression of  -synuclein. Because the interactions of synu-
cleins with lipid membranes are transient (Maroteaux and
Scheller, 1991; George et al., 1995), a significant pool of
synucleins could be dissociated from the organelles at any
given time, perhaps reaching a high enough local concentra-
tion of  -synuclein to induce self-association and fibril for-
mation. Interestingly, interaction of  -synuclein with syn-
thetic lipid droplets in cells promotes the formation of
oligomeric species (Cole et al., 2002). Further investigation
is necessary to lend support to this model.
Materials and methods
Animals
The generation of PS1 knockout and rescue mice was described elsewhere
(Wong et al., 1997; Qian et al., 1998). PS1  /  animals were mated, and
the pregnant dams were killed by cervical dislocation 15–16 d after con-
ception. Embryos were visually classified as PS1  /  or littermate control
mice (designated PS1  /? to include PS1  /  and  /  genotypes) by their
distinct morphological characteristics (Wong et al., 1997). For experiments
requiring either PS1  /  embryos or PS1  /  embryos rescued with hu-
man wild-type PS1 (PS1WT rescue) or PS1 carrying the FAD A246E muta-
tion (PS1A246E rescue), homozygous animals of each genotype were mated.
PS1  / , PS1WT rescue, and PS1A246E rescue mice were provided by H.
Zheng and S. Qian (Baylor College of Medicine, Houston, TX).
Cell culture
Cortices from mouse embryo brains were isolated and incubated in 0.1%
trypsin/HBSS/0.5 mM EDTA without Ca
2  or Mg
2  (Invitrogen), and cells
mechanically dissociated using a fire-polished pipette. Cells were plated in
Dulbecco’s minimum essential medium (DMEM)   10% FBS in poly-D-
lysine–coated 6-well plates at a density of 10
6 cells/well or on coated 10-
mm coverslips (Bellco Glass, Inc.) at a density of 10
5cells/well. 24 h after
plating, medium was replaced with DMEM plus B27 supplements (Invitro-
gen) to promote neuronal survival and inhibit growth of nonneuronal cells.
Neurons were used for experimentation 10 d after plating unless stated oth-
erwise. For pharmacological studies, staurosporine (Sigma-Aldrich), SKF
96365 (Sigma-Aldrich), thapsigargin (Sigma-Aldrich), or  -secretase inhibi-
tors MW-167, L-685,458, 2-Napthyl-VF-CHO, and WPE-III-21C (Calbio-
chem) were added to neurons in DMEM   B27 for the length of time indi-
cated. Primary fibroblasts were generated from PS1  /  and PS1  /? mice,
immortalized with v-myc, and maintained in DMEM   10% FBS.
Antibodies
To assay synucleins, the following antibodies were used: Syn 202, Syn
205, and Syn 214 (recognizing both  - and  -synuclein), SNL-1 (specific
for  -synuclein), Syn 207 (specific for  -synuclein), and Syn 303 (preferen-
tially recognizing a pathological conformation of  -synuclein). Mapping
and specificity of these antibodies has been documented previously (Gias-
son et al., 2000; Duda et al., 2002). Additionally, hu A is a rabbit poly-
clonal antibody raised to full-length recombinant  -synuclein that recog-
nizes multiple epitopes on both  - and  -synuclein. Other antibodies used
include those specific for synaptophysin (Boehringer), synapsin I (Molecu-
lar Probes, Inc.), Lamp-2 (ABL93; Iowa Developmental Hybridoma Studies
Bank; and C20; Santa Cruz Biotechnology, Inc.), NFL (Tu et al., 1995),
 -tubulin (Sigma-Aldrich), tau (14/46; Kosik et al., 1988,) and neuron-spe-
cific enolase (NSE; Polysciences, Inc.).
Immunocytochemistry
Cultures were fixed in 4% PFA (Electron Microscopy Sciences) in PBS for
30 min, and blocked and permeabilized using 5% horse serum plus 0.1%344 The Journal of Cell Biology | Volume 165, Number 3, 2004
saponin in PBS. Coverslips were incubated in primary antibody overnight
followed by the appropriate secondary antibody conjugated to either Texas
red or fluorescein (Jackson ImmunoResearch Laboratories). Coverslips were
mounted in Vectashield (Vector Laboratories) and analyzed using either a
confocal microscope (Leica) with software (Bio-Rad Laboratories), or an in-
verted microscope (Nikon) with CoolSnap software (Image Processing So-
lutions). To quantify synuclein-positive putative synapses, the number of
puncta immunoreactive for both synuclein and synaptophysin was com-
pared with the total number of synaptophysin-positive puncta.
Western blots
RIPA buffer (0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 5 mM
EDTA, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0) plus a cocktail of protease
inhibitors (1  g/ml each of leupeptin, pepstatin A, TPCK, TLCK, soybean
trypsin inhibitor, and 0.5 mM PMSF) was used to extract proteins from cor-
tical cultures and the resultant lysates were sonicated and spun at 100,000 g
for 20 min. 25  g of protein was resolved by SDS-PAGE on either 10% or
12% slab gels, electrophoretically transferred to nitrocellulose, and probed
with primary antibody followed with HRP-conjugated mouse or rabbit sec-
ondary antibodies and visualized by chemiluminescence. For quantitative
studies, blots were probed with an 
125I-labeled secondary antibody and
was analyzed by PhosphorImager (Molecular Dynamics, Inc.).
EM
Cortical neuronal cultures were fixed in 2% glutaraldehyde/PBS for 24 h,
dehydrated in a graded series of ethanols, and embedded in Epon. For EM,
blocks were cut on an UltracutE, stained with 1% uranyl acetate, and exam-
ined with a transmission electron microscope (model 1010; JEOL). For im-
muno-EM, coverslips were fixed briefly in 4% PFA/0.25% glutaraldehyde in
PBS, permeabilized with ethanol, incubated with hu A antibody, followed
by a goat anti–rabbit HRP-conjugated antibody (Santa Cruz Biotechnology,
Inc.), and developed with 3,3 -DAB. DAB was enhanced for immuno-EM
studies using a modification of the Rodriguez silver/gold enhancement
method (Teclemariam-Mesbah et al., 1997). Coverslips were then fixed in
2% glutaraldehyde/PBS overnight, and prepared as described above.
Northern blots
Total RNA was extracted from cortical cultures using the RNeasy kit
(QIAGEN). 5  g RNA was denatured and loaded onto 2% agarose-formal-
dehyde gels, then transferred and cross-linked to nitrocellulose (Hybond
N ; Amersham Biosciences). A synuclein-specific probe was prepared
from full-length  -synuclein cDNA, labeled with [
32P]-dCTP using DNA la-
beling beads (Amersham Biosciences) and purified using MicroSpin G-50
columns (Amersham Biosciences). Radioactive probe was hybridized to
the membrane using QuickHyb solution (Stratagene), and the membrane
was opposed to a PhosphorImager plate for analysis.
Translation assay
Cortical cultures were methionine-deprived for 30 min by incubation in
methionine-free DMEM (Invitrogen) before adding 500  Ci [
35S]methio-
nine (NEN Life Sciences Products) per milliliter of DMEM with 5% dia-
lyzed FBS (Invitrogen) for 1.5 h. Cells were rinsed twice with PBS and
scraped into CSK buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM EGTA,
1% Triton X-100, 1 mM PMSF, protease inhibitor cocktail). Lysates were
sonicated and spun at 100,000 g for 20 min. Cell lysates were immunopre-
cipitated with the antibody hu A using protein A/G agarose beads (Santa
Cruz Biotechnologies), and proteins were resolved by electrophoresis on
12% SDS-PAGE gels. Gels were fixed in 50% methanol and 5% glycerol,
dried, and exposed to a PhosphorImager screen.
Turnover assay
Cortical neurons cultured for 8 d in vitro were methionine deprived for 30
min in methionine-free DMEM before adding 500  Ci [
35S]methionine per
milliliter of DMEM with 5% dialyzed FBS for 2 h, after which the medium
was replaced with DMEM plus B27 supplement. Cells were rinsed twice
with PBS and scraped into CSK buffer at various times after the removal of
radioactive media. Lysates were sonicated, spun at 100,000 g for 20 min,
and immunoprecipitated with the antibody hu A using protein A/G beads.
Proteins were resolved by electrophoresis on 12% SDS-PAGE gels, fixed in
50% methanol plus 5% glycerol, dried, and exposed to a PhosphorImager
screen.
Immunohistochemistry
Postmortem hippocampal tissue from patients diagnosed with LBVAD or
controls was obtained from the brain bank of the Center for Neurodegener-
ative Disease Research, University of Pennsylvania. 12 cases of LBVAD (9
males, 3 females; mean age 77.3 yr, range 65–87 yr; mean postmortem in-
terval 13.2 h, range 3.5–46.5 h), 5 cases of PD (3 males, 2 females; mean
age 76.0 yr, range 69–83 yr; mean postmortem interval 8.7 h, range 5–15 h),
and 3 nondiseased control cases (2 males, 1 female; mean age 63.3 yr,
range 56–72 yr; mean postmortem interval 3.5 h, range 2–8 h) were ana-
lyzed. Tissue was prepared as described previously (Trojanowski et al.,
1989). In brief, tissue was fixed in 10% neutral-buffered formalin, rinsed in
50 mM Tris, and 150 mM NaCl, dehydrated through a graded series of eth-
anols into xylene at RT, infiltrated with paraffin, and cut into 6- m sec-
tions. Sections were then rehydrated, treated with 88% formic acid, and
quenched with 83% methanol/5% hydrogen peroxide before antibody ad-
dition. Sections were incubated with primary antibody in 0.1 M Tris, pH
7.6, plus 2% donor horse serum overnight at 4 C, then sequentially incu-
bated with species-specific biotinylated secondary antibody and avidin–bio-
tin complex (Vectastain ABC Elite kit; Vector Laboratories) for 1 h each at
RT, and finally visualized with DAB and counterstained with hematoxylin.
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